European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Related Questions
How will the EU approval of OGSIVEO impact PTC's short‑term stock price and trading volume?
What is the expected EU market size and revenue contribution from OGSIVEO, and how does it compare to existing treatments and competitors?
What regulatory, pricing, or reimbursement hurdles could affect OGSIVEO's rollout in other regions and its long‑term growth trajectory?